Emergent Biosolutions Inc. · NYSE:EBS
Emergent Biosolutions — 44th Annual J.P. Morgan Healthcare Conference (January 2026)
21 slides from Emergent Biosolutions's conference presentation, Jan 14, 2026
Slide 1: Combating Public Health Threats for Communities Around the World
Exhibit 99.1 Combating Public Health Threats for Communities Around the World th 44 Annual J.P. Morgan Healthcare Conference Joe Papa President and Chief Executive Officer January 14, 2026 1 1
Slide 2: Safe Harbor Statement/Trademarks
Safe Harbor Statement/Trademarks This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements, other than statements of historical fact, including statements regarding the future performance of the Compan
Slide 3: Company Overview
Company Overview 3
Slide 4: We Help Prepare for Today's Health Challenges and Tomorrow's Threats
We Help Prepare for Today’s Health Challenges and Tomorrow’s Threats* Our mission is to protect and save lives. $775 - $835M 11 11 2025 Revenue Guidance Products Biodefense/MCM Contract Mods & Product Orders YTD Global Strategic Partner 900+ Naloxone Market to governments, NGOs and Leadership Employ
Slide 5: Experienced and Trusted Management Team
Experienced and Trusted Management Team Experienced and Trusted Management Team Coleen Glessner Simon Lowry, M.D. Richard Lindahl Joseph Papa EVP, Quality, Ethics EVP, Chief Financial Officer Chief Medical Officer, Head of President and CEO and Compliance Research and Development Paul Williams Jessi
Slide 6: Multi-Year Transformation Plan to Create Shareholder Value
Multi-Year Transformation Plan to Create Shareholder Value 2026 and Beyond 2026 Transform 2024-2025 Turnaround (Underway) Business has been • Advance strategic transformation for long- stabilized and right-sized term growth and profitability • Focused on segment revenue growth and • Build synergisti
Slide 7: Most Diverse Biodefense/Medical Countermeasures and Naloxone Portfolio Globally
Most Diverse Biodefense/Medical Countermeasures and 1 Naloxone Portfolio Globally Complications Smallpox from Smallpox • ACAM2000® Vaccination • TEMBEXA® • CNJ-016® VIGIV • 25+ years of experience developing and manufacturing protections against critical public health threats Anthrax Mpox • Anthrasi
Slide 8: Biothreats: America's Growing Security Risk
Biothreats: America’s Growing Security Risk 1 New survey of 250+ policy opinion leaders reinforces significant risk of bioterrorism across U.S. 73% 73% of policy opinion leaders say a biological attack would be easier to carry out and nearly half see it as more likely than a nuclear strike 65% of po
Slide 9: Expanding the Presence of Our MCM Products in an Increasingly Dangerous World
Expanding the Presence of Our MCM Products in an Increasingly Dangerous World North America/U.S. Centric manufacturing for biodefense with additional capacity opportunities Canada • Lansing, MI Canada European Union • Winnipeg, Canada (NEW: now FDA-approved USA facility as the drug product manufactu
Slide 10: MCM Business: Supporting U.S. and International Governments' Biodefense Readiness
MCM Business: Supporting U.S. and International Governments' Biodefense Readiness and Supply Resilience Consistent and ongoing engagement with U.S. and international governments Global Strategic Partner to governments, NGOs and biopharma innovators International orders represent 34% of total MCM rev
Slide 11: Heightened Efforts to Combat the Opioid Overdose Epidemic
Heightened Efforts to Combat the Opioid Overdose Epidemic President Trump signed an Executive Order (Dec. 2025) designating illicit fentanyl and its core precursor chemicals as Weapons of Mass Destruction. CDC prelim data predicts 76,516 drug overdose deaths -24.5% (8 in 10 are caused by an opioid)
Slide 12: Naloxone Business: Leading With Purpose to Help Save Lives
Naloxone Business: Leading With Purpose to Help Save Lives NEW: FDA approves OTC NARCAN® Nasal Spray to be packaged in new carrying case–a unique option/solution to increase accessibility–COMING SOON! • While many factors are driving the reduction in opioid overdose deaths since 2023-2024, third-par
Slide 13: Multiple Growth Opportunities Ahead
Multiple Growth Opportunities Ahead We plan to Strong cash & invest to enable liquidity position sustainable, long-term enables additional growth. internal programs Expanding U.S. and external & international Exploring potential for business MCM orders and government-funded development opportunities
Slide 14: Near-Term Focus Maximizes Value of Current Assets and Pipeline/R&D Opportunities
Near-Term Focus Maximizes Value of Current Assets and Pipeline/R&D Development Opportunities Stage of Development Product/Candidate Disease Area Partner(s) Discovery Preclinical Phase 1 Phase 2 Phase 3 Submission Approved Ebanga * Zaire ebolavirus BARDA Smallpox BARDA TEMBEXA® Mpox PANTHER, Africa C
Slide 15: Financials
Financials 15
Slide 16: Improved Operating Efficiency Driving Increased Profitability & Cash Generation
Improved Operating Efficiency Driving Increased Profitability & Cash Generation (YTD as of 9/30/25) ($ in millions) 1 Total Revenues Adjusted EBITDA & Adjusted EBITDA Margin + 1,400 bps $194 $162 2 YTD Operating Cash Flow Improved Liquidity Year Over Year $96 Revolver Significant AR from late Septem
Slide 17: $100M Term Loan Paydown on December 29, 2025
$100M Term Loan Paydown on December 29, 2025 Gross Debt of $593M, ($275M) or (32%) versus year end 2023 Net Debt of $448M ($309M) or (41%) versus year end 2023 ($100M) Term Loan Paydown ü Used existing Balance Sheet Cash on December 2025 th December 29 to paydown $100M of Term Loan Principal Versus
Slide 18: Capital Allocation Priorities During 2026 Turnaround Period
Capital Allocation Priorities During 2026 Turnaround Period (YTD as of 9/30/25) Growth Investments Share Repurchase Debt Repayment $100M Term Loan Paydown December 2025 12 Month $50M Share International MCM growth 1 Net Debt $448M, a 19% reduction vs. Q3 Repurchase Program ending 2024 March 2026 Int
Slide 19: FY 2025 Revenue & Profitability Guidance, as of 10/29/25
FY 2025 Revenue & Profitability Guidance, as of 10/29/25 FY 2025 as of FY 2025 as of FY 2025 as of FY 2025 as of METRIC ($ in millions) October 29, 2025 August 6, 2025 May 7, 2025 March 3, 2025 Total revenues $775 - $835 $765 - $835 $750 - $850 $750 - $850 Net income $60 - $75 $40 - $65 $20 - $70 $1
Slide 20: Summary
Summary • On track with turnaround phase of multi-year plan • Reduced debt by $100M in December 2025 with continued focus on capital allocation strategies to drive value for stakeholders • Increased gross margin & profit follow through from 2024, generated through restructuring actions and improved
Slide 21: www.emergentbiosolutions.com
www.emergentbiosolutions.com 21
Emergent BioSolutions — 44th Annual J.P. Morgan Healthcare Conference (January 2026) on 6ix